Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor

NCT03746080 is registered in ClinicalTrials.gov with Lawrence D Recht as lead sponsor.

NCT NCT03746080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03746080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Lead sponsor
Lawrence D Recht
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2018
Completion date
February 8, 2024
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma with primitive neuronal component, gliosarcoma, malignant glioma, oligodendroglial component present